For patients undergoing percutaneous coronary intervention (PCI), tailoring antiplatelet therapy based on the results of platelet function testing makes no difference in the risk of recurrent ischemic ...
Use of platelet function testing during dual antiplatelet therapy, including a P2Y12 antagonist, in acute coronary syndromes does not improve clinical outcomes. Researchers at King's College London ...
Controversy regarding a possible role of proton pump inhibitors (PPIs) in interfering with the efficacy of dual antiplatelet therapy continues with a new study showing that pantoprazole—thought to be ...
Aortic-valve stenosis can be complicated by bleeding that is associated with acquired type 2A von Willebrand syndrome. However, the prevalence and cause of the hemostatic abnormality in aortic ...
Barcelona, Spain, 31 August: Studies from a growing body of convincing data show that responsiveness to antiplatelet therapy is real. This is a clinically important issue and there is a need to ...
HOUSTON--(BUSINESS WIRE)--Houston-based Aggredyne, Inc., a biomedical diagnostics company widely recognized as a leader in the field of platelet function testing, has appointed Dr. Jeffrey Dahlen as ...
November 17, 2006 (Chicago) -- Subjects enrolled in the Genetic Study of Aspirin Responsiveness (GeneSTAR) inadvertently helped Johns Hopkins University researchers measure chocolate's inhibition of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback